NCT06343311 2025-08-07
STARLIGHT-1
Estrella Immunopharma, Inc.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT01193842 2023-11-21
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02228512 2018-08-31
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn